1. Home
  2. TXG vs LQDA Comparison

TXG vs LQDA Comparison

Compare TXG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXG
  • LQDA
  • Stock Information
  • Founded
  • TXG 2012
  • LQDA 2004
  • Country
  • TXG United States
  • LQDA United States
  • Employees
  • TXG N/A
  • LQDA N/A
  • Industry
  • TXG Biotechnology: Laboratory Analytical Instruments
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • TXG Industrials
  • LQDA Health Care
  • Exchange
  • TXG Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • TXG 1.3B
  • LQDA 1.3B
  • IPO Year
  • TXG 2019
  • LQDA 2018
  • Fundamental
  • Price
  • TXG $8.85
  • LQDA $14.52
  • Analyst Decision
  • TXG Buy
  • LQDA Strong Buy
  • Analyst Count
  • TXG 16
  • LQDA 7
  • Target Price
  • TXG $20.00
  • LQDA $28.33
  • AVG Volume (30 Days)
  • TXG 3.0M
  • LQDA 887.5K
  • Earning Date
  • TXG 04-29-2025
  • LQDA 03-19-2025
  • Dividend Yield
  • TXG N/A
  • LQDA N/A
  • EPS Growth
  • TXG N/A
  • LQDA N/A
  • EPS
  • TXG N/A
  • LQDA N/A
  • Revenue
  • TXG $610,785,000.00
  • LQDA $13,996,000.00
  • Revenue This Year
  • TXG $1.43
  • LQDA $256.78
  • Revenue Next Year
  • TXG $8.86
  • LQDA $222.00
  • P/E Ratio
  • TXG N/A
  • LQDA N/A
  • Revenue Growth
  • TXG N/A
  • LQDA N/A
  • 52 Week Low
  • TXG $8.53
  • LQDA $8.26
  • 52 Week High
  • TXG $37.74
  • LQDA $16.81
  • Technical
  • Relative Strength Index (RSI)
  • TXG 33.15
  • LQDA 45.00
  • Support Level
  • TXG $9.65
  • LQDA $14.41
  • Resistance Level
  • TXG $10.60
  • LQDA $15.09
  • Average True Range (ATR)
  • TXG 0.51
  • LQDA 0.65
  • MACD
  • TXG -0.06
  • LQDA -0.06
  • Stochastic Oscillator
  • TXG 13.68
  • LQDA 26.37

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: